The American Journal of Medicine
Volume 120, Issue 1 , Pages 98.e9-98.e16 , January 2007

Impact of NSAIDS on Mortality and the Effect of Preexisting Coronary Artery Disease in US Veterans

  • Todd A. Lee, PharmD, PhD

      Affiliations

    • Midwest Center for Health Services and Policy Research, Hines Veterans Affairs Hospital, Chicago, Ill
    • Institute for Healthcare Studies and Division of General Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill
    • Corresponding Author InformationRequests for reprints should be addressed to Todd A. Lee, Midwest Center for Health Services and Policy Research, Hines VA Hospital (151-H), PO Box 5000, Hines, IL 60141.
    • ,
  • Brian Bartle, MPH

      Affiliations

    • Midwest Center for Health Services and Policy Research, Hines Veterans Affairs Hospital, Chicago, Ill
    • ,
  • Kevin B. Weiss, MD, MPH

      Affiliations

    • Midwest Center for Health Services and Policy Research, Hines Veterans Affairs Hospital, Chicago, Ill
    • Institute for Healthcare Studies and Division of General Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill

References 

  1. Bombardier C, Laine L, Reicin A, et al. VIGOR Study Group Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343(21):1520–1528
  2. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092–1102
  3. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365(9458):475–481
  4. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med. 2005;142(3):157–164
  5. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med. 2005;142(7):481–489
  6. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363(9423):1751–1756
  7. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954–959
  8. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352(11):1081–1091
  9. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360(9339):1071–1073
  10. Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullins CD. Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Arch Intern Med. 2005;165(2):181–186
  11. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109(17):2068–2073
  12. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071–1080
  13. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001;104(19):2280–2288
  14. Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J. 2003;146(4):591–604
  15. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;330(7504):1366
  16. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364(9450):2021–2029
  17. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med. 2003;163(4):481–486
  18. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet. 2002;359(9301):118–123
  19. Topol EJ. Arthritis medicines and cardiovascular events—“house of coxibs.”. JAMA. 2005;293(3):366–368
  20. Cowper DC, Ripley BA, Kuebeler MK, Yu W, Kubal JD, Manheim LM. VA Health Care Atlas, FY-2000. Rehabilitation Outcomes Research Center, Department of Veterans Affairs 2003 October. Available at: http://www.vard.org/rorc/VA_healthcare_atlas.htm. Accessed March 9, 2005.
  21. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med. 2003;168(1):49–53
  22. Page WF, Braun MM, Caporaso NE. Ascertainment of mortality in the U.S. veteran population: World War II veteran twins. Mil Med. 1995;160(7):351–355
  23. Page WF, Mahan CM, Kang HK. Vital status ascertainment through the files of the Department of Veterans Affairs and the Social Security Administration. Ann Epidemiol. 1996;6(2):102–109
  24. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics. 1984;40(1):63–75
  25. Robins JM, Gail MH, Lubin JH. More on “Biased selection of controls for case-control analyses of cohort studies.”. Biometrics. 1986;42(2):293–299
  26. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000;102(8):840–845
  27. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165(5):490–496

 The Midwest Center for Health Services and Policy Research, Hines VA Hospital provided funding. The funding agency had no role in any aspect of the study.The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or of the United States Government.

PII: S0002-9343(06)00270-1

doi: 10.1016/j.amjmed.2006.03.003

The American Journal of Medicine
Volume 120, Issue 1 , Pages 98.e9-98.e16 , January 2007

Article Tools

* Image Usage & Resolution